In this episode of the Plant Medicine Podcast, Dr. Mark Braunstein returns to discuss potential concerns surrounding the use of ketamine, especially use which is not overseen by a knowledgeable medical professional. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. Additionally, Dr. Braunstein is involved in multiple projects focused on expanding access, awareness, research, and safety in the field of psychedelics.   To begin this conversation, Dr. Braunstein shares how his original exposure to ketamine wasn’t in a medicinal context, but rather as a recreational drug of abuse. However, since then he has seen the transformative effects this substance can have on patients when used in a physician-directed context and for therapeutic purposes. Nonetheless, Dr. Braunstein stresses that this does not mean ketamine use does not come with certain risks.   Ketamine can be addictive and even carries a risk of overdose, particularly when used recreationally in a context where the purity of the substance is unknown. Dr. Braunstein distinguishes recreational and therapeutic uses of ketamine, explaining that recreational doses are often lower and dosing is more frequent, whereas ketamine is used in high doses in a therapeutic context, with extended periods between sessions.   Dr. Braunstein stresses both the responsibility of physicians and of patients to ensure ketamine is prescribed responsibly and used as directed. Despite the dangers posed by recreational ketamine use Dr. Braunstein describes in this conversation, it is still a medicine he believes can have significant positive impacts for patients. This requires, however, that it not be treated merely as yet another quick fix pill. Instead, Dr. Braunstein emphasizes that ketamine treatment ought to coincide with psychotherapeutic work. This combination, he says, will maximize the therapeutic potential of ketamine while also helping to ensure that the medicine is used responsibly, under the close direction of a medical professional.   In this episode:   The addiction and overdose potential with recreational ketamine use How dosage can dramatically change the effects of ketamine Responsible prescribing practices for physicians working with ketamine The psychological and physiological harms of ketamine abuse How Dr. Braunstein talks to his patients about responsible use before prescribing ketamine The importance of combining psychedelic medicines with psychotherapeutic work   Quotes:   “Part of why ketamine works is because it lights up your brain in all these different ways and when done occasionally, intentionally, it moves you. But if you’re always doing that, it ends up having the reverse effect, causing damage.” [12:56]   “This is a heavy-duty medication that, if you cross the line, can cause you to stop breathing and then die. So there is an actual, real danger to ketamine.” [16:25]   “I think the organ that is most prone to damage from overuse of ketamine is the same organ we are touting it fixing: the mind.” [18:39]   “When we think about these medications, we should think about combining them with therapy and not just taking these medications as medications… So that’s why with ketamine I’m really recommending it with therapy.” [25:04]   Links:   Reconscious Medical Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast features a conversation with Shannon Carlin, MA, LMFT, to discuss how to become an MDMA-assisted therapist, including a discussion of the MAPS training program. Shannon is the Director and Head of Training and Supervision at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit where she oversees the development and implementation of clinical training programs that prepare mental health and medical professionals to deliver MDMA-assisted psychotherapy in approved clinical settings. Shannon started working with MAPS in 2011 before joining MAPS PBC in 2016.   In this conversation, Shannon discusses her personal background and some of the nuances of psychedelic-assisted therapy. Shannon shares her experiences being trained as an MDMA facilitator in 2014 when this therapy was much less mainstream and mentions how much the program has grown and evolved since then. In discussing her own background with various forms of therapeutic work, Shannon emphasizes the unique client relationship obtained in the longer sessions of MDMA therapy, saying that this therapy is very well-suited to meeting people in their time of need.   Shannon also discusses the details of the 100-hour MDMA-assisted therapy training program she leads and supervises at MAPS. The program consists of an online course, a training retreat with senior MDMA-assisted psychotherapy researchers, and opportunities for experiential and didactic learning.    Shannon additionally touches on the topic of MDMA therapists-in-training undergoing this treatment themselves as a learning experience, stating that this is an opportunity MAPS tries to make available and that many of those who have had this opportunity found it beneficial to their future work with MDMA in a therapeutic context. In closing, Shannon discusses MAPS’ commitment to equity and mentions that some scholarships will be available for the training program.   The MAPS MDMA Therapy Training Program is now accepting applications from trained mental health and medical practitioners. To learn more, visit https://mapspublicbenefit.com/training   In this episode:   How MDMA therapy differs from traditional talk therapy The importance of nurses and other paraprofessionals in MDMA-assisted psychotherapy  The history of the use of MDMA in therapeutic contexts prior to prohibition  Current training programs in psychedelic-assisted psychotherapy  The future of legal MDMA use in therapy What skills translate from MDMA psychotherapy to other forms of psychedelic psychotherapy  How to enroll in the next round of MAPS MDMA training   Quotes:   “Our training program really focuses a lot on the therapeutic relationship in MDMA therapy and the ways that that relationship changes, deepens, becomes more complex.” [13:20]   “As we do our training program we have a really multidisciplinary group. We have physicians and psychiatrists and we have nurses, we have psychiatric nurses, social workers, therapists, psychologists, clergy people.” [15:56]   “We work in a cotherapy model so every session has two providers in the room, so we always have one person who is licensed to practice psychotherapy and then we have flexibility about exactly what the role of the second person is.” [26:09]   “We’re looking at possibly MDMA-assisted therapy becoming a legal treatment medicine, not only in the US, but in multiple countries, even as soon as in the next two years.” [28:21]   “It’s really difficult to do healthy volunteer therapist studies because the FDA thinks about clinical trials in terms of treating a disease.” [35:21]   Links:   MAPS MDMA Therapy Training MAPS Public Benefit Corporation Psychedelic Medicine Association Porangui

This week’s episode of the Plant Medicine Podcast features a conversation with Rebecca Kronman, LCSW on the intersection of psychedelics and parenting. Rebecca is a licensed therapist with a private practice in Brooklyn, New York, where she helps clients integrate and prepare for psychedelic experience, in addition to providing therapeutic care for clients struggling with mental illnesses such as anxiety or depression. Rebecca is also the founder of Plant Parenthood, which is an online and in-person community of parents who use psychedelics, plant medicine and cannabis looking to de-stigmatize the conversation around psychedelics and parenting.  In this wide-ranging discussion, Rebecca explores both practical and theoretical issues in the intersection of psychedelics and parenthood. The most controversial of these being, of course, minors using psychedelics themselves. Rebecca discusses the traditional cultural frameworks in societies which use psychedelics and how they handle this matter, contrasting this with the Western medical model where psychedelic use is highly stigmatized yet prescribing amphetamines to children is rather uncontroversial. Rebecca emphasizes that this is a topic which deserves more careful consideration, as ketamine treatments are already available and effective for treatment-resistant depression in teens. She also discusses how psychedelics can help us reparent ourselves and heal generational trauma, both of which can aid in improving parents’ relationship to not only their children, but to their own parents as well. In addition, Rebecca discusses some practical concerns, such as how parents ought to discuss psychedelic use with children. Here she draws a distinction between proactive and reactive conversations, the former being initiated by the parent, the latter by the child. Choosing to pursue a degree of proactive discussion with children around psychedelic use can have a positive impact, both in strengthening trust and openness between parent and child as well as preparing older children for encountering these things in their own lives as accessibility and awareness continue to increase. Rebecca closes this discussion talking about the high levels of scrutiny parents face socially, emphasizing the importance of parents having the opportunity to come together around this topic to determine the best solutions for their own families. In this episode: The future of psychedelic medicines for minors How psychedelics can inform one’s approach to parenting Taking psychedelics with family members Including children in integration practices Proactive vs reactive conversations about substance use with children Plant Parenthood’s upcoming events   Quotes: “It’s something that needs to be on our minds: how do we approach this topic without stigmatizing it so that when our children inevitably find out about it, we can have an open dialogue.” [11:39] “A lot of the work of psychedelics, is the work of reparenting yourself. It’s the work of healing intergenerational trauma.” [16:49] “For some parents it’s not a problem for their children to be around during their psychedelic experience itself, and for some parents they feel like ‘you know what, I want this time for myself–this is my time to go inward, to journey into my psyche, and I don’t want to be a parent during that moment.’” [24:25] “We can start talking about plant medicine or substance use or addiction from the very earliest time our kids can understand.” [29:28] “As kids get older it does become more important to be a bit more proactive because the reality is they will be exposed to this, especially as access increases.” [32:43] “There is a level of scrutiny that parents face that is different than what other people face and it makes people more reticent to be honest and to approach these topics in a way that feels healing and that feels complete.” [41:29] “[Psychedelics] make us be able to inhabit that open, neuroplastic state that children naturally inhabit. So in a sense, it makes us be able to understand them better. It makes us be able to get into their experience in a deeper way.” [46:42]   Links: Plant Parenthood Website Plant Parenthood Instagram Plant Parenthood Facebook Plant Parenthood YouTube Rebecca’s website Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, researcher Chris Timmermann, PhD joins to discuss his recent publication regarding psychedelic apprenticeship. Dr. Timmermann is a researcher at the Center for Psychedelic Research at Imperial College London where he conducted the first neuroimaging studies of DMT in healthy volunteers to explore potential mental health impacts. He is also the president and founder of the Foundation for the Study of Human Consciousness in Chile. Dr. Timmermann’s paper "Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations" was recently published in December 2020 and it provides a framework for tackling the difficult problem of mediating knowledge gained during psychedelic experiences. In this conversation, Dr. Timmermann breaks down his article and discusses how different contexts for psychedelic use (such as therapeutic, neo-shamanic, and research) each come with their unique concerns in terms of the knowledge these experiences can induce.  Highlighting the fact that it is the same mechanism causing both therapeutic benefits and potential distress following psychedelic experience, Dr. Timmerman explains that psychedelic guides and even researchers can profoundly influence the content of a psychedelic experience. His framework for apprenticeship seeks to address how guides and researchers can best wield this influence positively, and provides suggestions for how to better approach the integration of experiences which feature visions or insights that can be difficult to understand and internalize. In this episode: Dr. Timmermann’s framework for psychedelic apprenticeship Why psychedelic revelations can be a double-edged sword Psychedelic insights and vision in therapeutic, neo-shamanic, and research contexts Spiritual bypassing in the psychedelic community  What gives psychedelic or mystical visions their sense of authority Quotes: “There is a strong need for an intersubjective component to validate this knowledge, these revelations, these insights.” [8:45] “The striking thing that I thought was really important was that it seems to be the same mechanism which drives the benefits but also drives the complications.” [15:58] “The broader culture is inviting some sorts of narratives and experiences and because the psychedelic state is a permeable state, the system is porous to these narratives and memes.” [33:33] “This process of apprenticeship essentially is a framework for us to understand how we can help make sense of these experiences for people, how they can approach the experience, but with a light touch.” [41:55] “What we’re doing with the science and what we’re doing with these papers and so on is providing some form of context, some form of mediation, some form of knowledge to try to contain these experiences a bit more.” [50:26] Links: Dr. Chris Timmermann on Twitter Center for Psychedelic Research at Imperial College London Dr. Timmermann’s recent paper “Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations” Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast features a conversation with Erica Siegal about the intricacies of harm reduction. Erica is a licensed clinical social worker and a professional harm reductionist, as well as an MDMA-assisted psychotherapy researcher. She is the founder of NEST Harm Reduction, a California-based clinical practice that offers private therapy, harm reduction training, workplace consulting, and direct care of workers on the frontlines of secondary trauma.  In this discussion, Erica shares the basic principles underlying harm reduction while also unpacking the nuances involved in providing care. The four principles Erica shares from the Zendo project are: 1) creating a safe space, 2) sitting, not guiding, 3) talking through rather than talking down, and 4) remembering difficult is not the same as bad. These principles provide a basic framework for providing harm reduction services for someone who has chosen to experiment with psychoactive substances.  Erica also discussed the acronym SPACE, which stands for sustainable, patient, authentic, consensual, and empathetic, with each of these terms playing a crucial role in effective harm reduction work. Sustainable refers to the emotional and energetic toll this work can take, and ensuring one isn't spread too thin and heading towards burnout. Patience is necessary when engaging with someone who is going through a challenging experience, especially when their needs are shifting or they are having difficulties communicating.  Erica describes authenticity in the harm reduction context as staying grounded in one's training and expertise and not trying to improvise modalities while sitting. Consent is also crucial when providing care, and Erica explains how to approach this topic both in the context of a pre-planned psychedelic experience and when the opportunity for harm reduction arises more spontaneously. Finally the harm reductionist should strive to be empathetic, providing proactive support through open communication and attempting to meet needs as they arise. In this episode: The four guiding principles of psychedelic harm reduction Why romantic partners often don't make the best trip sitters The intricacies of consent in a harm reduction setting Dealing with burnout as a harm reduction professional  How to hold space in an authentic, empathetic way Gamifying harm reduction Quotes: "Harm reduction is a movement for people who believe in human rights and dignity for anybody, including people who are actively using drugs." [5:31] "When we go into an altered state or use psychedelics, we are obviously shifting our perspective and therefore we need to make sure we have some safe things that can ground us back into our bodies and our experiences." [11:57] "If you are burning out and you are becoming someone who needs help, you're not actually holding the space to do the work." [19:32] "I think all psychedelic practitioners, whether you are above ground or underground, should provide informed consent to clients." [30:23] "The only things that we do with somebody who is that significantly altered is be patient with them, and wait for them to be able to make decisions for themselves." [36:29] "Make sure you're checking in about peoples' basic needs because they forget. And that could be the thing that shifts it onto the right direction for them." [49:54] Links: NEST Harm Reduction Psychedelic Medicine Association Porangui

This first episode of the Plant Medicine Podcast in 2021 features a conversation with Dr. Reid Robison, discussing the potentials of using psychedelics to treat eating disorders. Dr. Robison is a board-certified psychiatrist and the chief medical officer at Novamind. He is also the co-founder of Cedar Psychiatry, founder of the Polizzi Free Clinic, and adjunct faculty at the University of Utah. Dr. Robison serves as the medical director of Center for Change—a top eating disorder treatment center—and he is currently the coordinating investigator for the upcoming MAPS study looking at the potential for MDMA-assisted psychotherapy as a treatment for eating disorders. In this conversation, Dr. Robison dissects the intricacies of various eating disorders and shares his experience using ketamine-assisted psychotherapy. At Center for Change, Dr. Robison conducted an IRB-approved study looking at the use of ketamine as a potential treatment for eating disorders. In the study, participants were regularly administered ketamine in a small group setting with therapeutic and integration work happening between sessions. Dr. Robison shares some anecdotal reports as well as the objective data from the study, both of which show promising results. In particular, Dr. Robison notes how ketamine can promote a sense of embodiment for individuals struggling with eating disorders, helping them return to a more intuitive connection with food and eating.  Additionally, Dr. Robison discusses topics such as neuroplasticity and the default mode network as potential key factors explaining why this type of treatment could be effective. Since compounds such as ketamine can promote neuroplasticity and downregulate the default mode network, this gives the therapist a window to do particularly effective work with the patient, as they are in a more malleable state and less burdened by routines and habitual thought patterns. Dr. Robison closes with a discussion of the upcoming MAPS study which will look at the possible efficacy of MDMA-assisted psychotherapy for anorexia and binge eating disorders.  In this episode: Dr. Robison's study of ketamine-assisted psychotherapy for eating disorders The therapeutic modalities Dr. Robison's team uses alongside ketamine for addressing eating disorders Psycholytic vs transformative applications of ketamine in psychotherapy The co-occurrence of eating disorders and conditions such as depression, anxiety, and PTSD Details of the upcoming MAPS study on MDMA-assisted psychotherapy for anorexia and binge eating disorder. Quotes: "If you look at eating disorders, they're pretty underfunded and there are no FDA approved medicine treatment options for anorexia, for example." [3:25] "Ketamine and other psychedelic medicines are therapy aids, therapy boosters, accelerators, or catalysts to the therapeutic process." [10:42] "But I do believe that there are lasting benefits, especially when you pair it with the psychotherapy—when you have this window of opportunity of neuroplasticity to do some deeper work." [21:07] "Healing can be disruptive sometimes and you do feel worse before you feel better in some cases." [25:23] "Downregulation of the default mode is such a powerful and welcome break from the day-to-day patterns in these conditions." [37:43] Links: Novamind Cedar Psychiatry Center for Change Upcoming MAPS study on MDMA-Assisted Psychotherapy for Eating Disorders Psychedelic Medicine Association Porangui  

Today’s episode is the first in our series focusing on psilocybin’s potential uses as medicine. You are going to hear from one of the premier researchers into this drug, how he runs his studies, and what he has discovered concerning its effects and uses as a medicine. Dr. Albert Garcia-Romeu is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine and a Guest Researcher at the National Institute on Drug Abuse Intramural Neuroimaging Research Branch. There, he studies the effects of psychedelic drugs in humans with a particular focus of psilocybin as a potential aid in the treatment of addiction. Dr. Garcia-Romeu explains the biochemical effects of psilocybin in the human body. He delves into what his research has uncovered about the drug’s potential to treat addiction disorders. What is noteworthy about his research is that is has shown that psychedelic treatments have been able to help some people make lasting changes in regard to alcohol and nicotine addiction. Dr. Garcia-Romeu also discusses psilocybin’s use in treating anxiety and depression. The research has shown that psilocybin has the potential to help patients with life-threatening and terminal illnesses cope with the psychological burdens of their disease. He also explains some of the ongoing research into the efficacy of psilocybin to have a lasting impact on depression in general.   In this episode: How psilocybin works at a biochemical level What the research is saying about the uses of psilocybin to treat addiction disorders Possible reasons why some people respond more significantly to psilocybin treatments than others Psilocybin’s effect on treating mood disorders, such as anxiety and depression Safeguards to avoid possible adverse effects during psilocybin studies   Quotes: “Administering high doses of drugs like psilocybin and LSD seemed to really help people make some breakthroughs into having greater insight into their alcohol abuse and having more plasticity in their ability to change their behavior going forward.” [7:06] “The more mystical effects that people are having, the better outcomes you’re seeing.” [23:25] “These were real improvements in the quality of life that were measurable, statistically significant, and enduring.” [28:42]   Links: Get 20% off everything at Octogon Biolabs with coupon code 'plantmedicine’ Johns Hopkins Center for Psychedelic & Consciousness Research clinicaltrials.gov   Check out the full episode post Keep up with everything Plant Medicine related here Porangui

Dr. Dan Engle is a psychiatrist with a clinical practice that combines aspects of regenerative medicine, psychedelic research, integrative spirituality, and peak performance.  His medical degree is from the University of Texas at San Antonio. His psychiatry residency degree is from the University of Colorado in Denver, and his child and adolescent psychiatry fellowship degree is from Oregon Health & Science University.  Dr. Engle is an international consultant to several global healing centers facilitating the use of long-standing indigenous plant medicines for healing and awakening.  He is the Founder and Medical Director of Kuya Institute for Transformational Medicine in Austin, Texas; Full Spectrum Medicine, a psychedelic integration and educational platform; and Thank You Life, a non-profit funding stream supporting access to psychedelic therapies.  Dr. Engle is the author of The Concussion Repair Manual: A Practical Guide to Recovering from Traumatic Brain Injuries, as well as his new book, A Dose of Hope: A Story of MDMA-Assisted Psychotherapy. Dr. Engle shares how he sees ayahuasca and other plant medicines as a bridge between traditional medical practices and contemporary medicine. This is particularly the case in the field of psychology. Ayahuasca can have the ability to create visionary states that lend insight into what individuals find most important at a deep subconscious level. There are ongoing efforts to understand the possible uses of ayahuasca as a tool in integrative therapy. Dr. Engle has particular experience applying it in TBI therapies. He describes what he has observed in how ayahuasca can create synaptic genesis and stimulate the growth of brain cells. This has huge implications for treating neurodegenerative conditions.  Dr. Engle goes on to describe some of the scientific research surrounding ayahuasca. Its ability to treat a number of conditions has been closely examined in recent decades. This includes its effects on such a large range of issues including chronic inflammatory bowel conditions, addiction, depression, and brain injury.    In this episode: The potential of ayahuasca to lend insight into unconscious desires Uses of ayahuasca in integrative psychology and TBI treatments What ayahuasca is and the active chemicals it contains Known contraindications of ayahuasca  The findings of many of the research projects focusing on ayahuasca  Ayahuasca’s potential to treat addiction The lasting positive and negative effects of ayahuasca use   Quotes: “The opening that happens when medicines are facilitated well is orders of magnitude more powerful than the opening that I had experienced in talk therapy.” [6:30] “If you have brain trauma, or a neuro deficit or hypoactivity, many people feel like their brains come back online.” [19:16] “We started studying it. But we’re still in our infancy of understanding, whereas the traditional cultures have been working with this medicine for thousands of years.” [31:14] “The medicines are not here to save us. They aren’t here to fix us. The medicines are here to show us truth in our path. It’s still our work to do.”  [50:05]   Links: The Concussion Repair Manual “Fantastic Fungi” DMT: The Spirit Molecule “Embrace of the Serpent” Fellowship of the River Takiwasi Center Revive Centers Being True to You The Third Wave Check out the full episode post Keep up with everything Plant Medicine related here Porangui   The information provided in this podcast is for general informational purposes only and does not constitute the practice of medicine or other professional health care services, including the giving of medical advice. The content of this podcast is not intended to be a substitute for professional medical recommendation, diagnosis, or treatment. The use of information in this podcast is at one’s own discretion, and is not an endorsement of use given the complexity inherent in these medicines, and the current variable widespread illegality of their usage. 

This episode of the Plant Medicine Podcast features a conversation with Dr. Mark Braunstein discussing the potentials of cannabis-assisted psychotherapy. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. In his own practice as a psychiatrist, Dr. Braunstein employs both cannabis and ketamine to meet the individual needs of his patients. Dr. Braunstein stresses how he came to these modalities after becoming disillusioned with the predominant model of psychiatry and its emphasis on treating symptoms with pharmaceuticals without much consideration for the patient as an individual. With cannabis-assisted psychotherapy, Dr. Braunstein started to notice real changes in his patients, allowing them to begin living more fulfilling lives.  In this conversation, Dr. Braunstein discusses many of the intricacies of using cannabis in his practice as a psychiatrist, giving particular attention to the intake process he uses to determine which method of ingestion and what dosage would be appropriate for a particular patient given their specific condition and history. Dr. Braunstein also distinguishes between psycholytic and psychedelic applications of cannabis, explaining that the low dose, psycholytic approach is suited to the context of talk therapy, where cannabis helps encourage new insights without being too disorienting, whereas the psychedelic modality uses higher doses to allow the patient to explore their psyche on their own within a safe, supportive context.  In this episode: How wilderness therapy made Dr. Braunstein reevaluate his understanding of psychiatry Psycholytic vs psychedelic uses of cannabis for therapeutic purposes How Dr. Braunstein approaches patients as unique individuals when considering treatment options Using cannabis to help patients encounter buried traumas in a safe, therapeutic setting Contradictions for cannabis-assisted psychotherapy Quotes: "It increases someone's ability to be more productive in psychotherapy-you're able to talk, see things in a different way, have different perceptions." [13:15] "Cannabis is so readily accessible for so many people and they can safely do it in the comfort of their home while they engage in teletherapy." [14:40] "We want to put people into categories of usage to help come up with a protocol of what dose we're going to start them on." [19:18] "Sometimes we'll actually do some cannabis-assisted psychotherapy first to help them process and move through some of the trauma, and then we'll move on to the ketamine to work on the depression." [26:20] "Yes, guidelines are important, but I think that having well-educated physicians, having extensive, well-educated conversations with our patients, and making the right decisions is the best way to go." [34:08] Links: Reconscious Medical Psychedelic Medicine Association Porangui  

In this episode of the Plant Medicine Podcast, Dr. James Fadiman and Adam Bramlage join to discuss the finer points of microdosing and their upcoming Microdosing Movement course. Dr. Fadiman is a world-renowned psychedelic researcher and transpersonal psychologist who has made seminal contributions to the contemporary understanding of microdosing coach with clients from a wide range of backgrounds to help craft individualized protocols to best harness the potentials of microdosing. Together with the San Francisco Psychedelic Society and Jakobien & Hein of The Microdosing Institute, they will be leading the upcoming six-week Microdosing Movement course.  In this discussion, Dr. Fadiman and Adam touch on many nuanced topics relating to microdosing, ranging from individualized protocols to current research. Dr. Fadiman tells of his experience gathering information on microdosing through his own study and how this originated what became known as the Fadiman protocol for microdosing. Dr. Fadiman also discusses some conclusions that can be drawn from experience reports, such as the efficacy of microdosing for combatting conditions such as addiction or depression.  Additionally, Adam shares the details of the Microdosing Movement course, emphasizing how building community is foregrounded in the course design. In addition to lectures by experts like Dr. Fadiman, participants will have the opportunity to socialize with other students, integrate the content, and ask questions at weekly communiTEA gatherings over Zoom. The microdosing movement course runs from Sunday, December 13th through Tuesday, January 19th. Additional information and registration linked below: Dr. Fadiman can be reached at jfadiman@gmail.com. In this episode: How Dr. Fadiman developed his microdosing protocol What we know about tolerance when it comes to psychedelics Recent research findings suggesting microdosing could also be effective in treating pain Details of the upcoming microdosing movement course How community enriches microdosing outcomes Quotes "The most important thing to get across is that each person is an individual and no one protocol is going to work for everybody. Everybody has different needs." [12:42] "And particularly people are saying, not that meditation improves your microdosing, but that microdosing absolutely improves your meditation." [15:36] "We're just seeing extremely positive results across the board, and we're seeing that the longer people microdose, the less often they need to microdose." [41:40] "There's so many different applications for this, with so many different conditions, and each day I get new emails or new contracts from people who are using it for totally new things." [43:54] Links The Microdosing Movement Course Microdosing Psychedelics Website Dr. Fadiman's Website Psychedelic Medicine Association Porangui